Teva Pharmaceutical Industries (NYSE:TEVA) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Teva Pharmaceutical Industries received a "Sell (D-)" rating from Weiss Ratings, despite some brokerages upgrading their price targets and ratings for the stock.
• Analysts have set a consensus rating of "Buy" for Teva with an average price target of $25.57, reflecting optimism despite recent challenges.
• The company's recent earnings report showed a slight revenue increase year-over-year, but revenue fell short of analyst expectations, highlighting ongoing financial pressures.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

A number of other brokerages have also weighed in on TEVA. UBS Group upped their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an "overweight" rating in a research note on Friday, October 3rd. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $25.57.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $18.95 on Friday. The stock's 50-day simple moving average is $19.08 and its 200 day simple moving average is $17.26. The stock has a market capitalization of $21.73 billion, a price-to-earnings ratio of -118.41, a price-to-earnings-growth ratio of 1.05 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's quarterly revenue was up .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Research analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insider Activity

In other news, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently modified their holdings of the company. Ion Asset Management Ltd. increased its position in shares of Teva Pharmaceutical Industries by 6.5% during the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock valued at $599,945,000 after purchasing an additional 2,383,500 shares during the last quarter. Menora Mivtachim Holdings LTD. grew its position in Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company's stock worth $645,148,000 after acquiring an additional 9,303,978 shares during the last quarter. Phoenix Financial Ltd. grew its position in Teva Pharmaceutical Industries by 31.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company's stock worth $632,882,000 after acquiring an additional 9,094,372 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its position in Teva Pharmaceutical Industries by 51.4% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company's stock worth $559,622,000 after acquiring an additional 11,334,780 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its position in Teva Pharmaceutical Industries by 8.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company's stock worth $480,768,000 after acquiring an additional 2,350,000 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.